Drugs / Faecal Microbiota Transplant
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT04361097 | Aug 2018 → Nov 2019 | diabetic kidney disease, hypertensive nephropathy | Hospital Universitario Dr. Jose E. Gonzalez | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06286709 Comparator | Mar 2024 → Apr 2026 overdue | inflammatory bowel disease, primary sclerosing cholangitis | University of Birmingham | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Faecal microbiota transplant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04361097 ↗ |
| Known as | FMT | “Faecal Microbiota Transplant (FMT)” NCT06286709 ↗ |
| Action | Restore | “It is believed that Faecal Microbiota Transplant (FMT) treatment can restore the balance in the gut microbiome” NCT06286709 ↗ |
| Route | Oral | “ingested orally” NCT04361097 ↗ |